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BACKGROUND
•
•

•

•

•

PATIENT CASE

Marijuana is one of the most commonly utilized recreational drugs and is widely known for both its
anti-emetic and appetite-stimulating properties
Medicinal-grade marijuana has been available for patients suffering from various medical
conditions, such as chemotherapy-induced nausea and vomiting, for example; it also has been
utilized in patients with chronic pain, in addition to a number of other disease states

History of Present Illness
•

•

While casual, intermittent use elucidates the aforementioned positive effects, chronic use of large
quantities of marijuana may precipitate the contrary, such as extensive nausea and vomiting, a
hallmark of Cannabinoid Hyperemesis Syndrome (CHS)

•

CHS is hypothesized to result from alterations within the endocannabinoid system. The
endocannabinoid system is involved in various physiologic processes throughout the body, and
contains two vital cannabinoids, CB1 and CB2, which are located within the central nervous system
(CNS) and gastrointestinal tract (GI)

•

Of note, CHS is similar in presentation to another disorder, Cyclic Vomiting Syndrome (CVS); the two
are often confused, or even misdiagnosed

PATHOPHYSIOLOGY
CB1

1

Agonism: reduction of nausea/vomiting
Antagonism: worsen nausea/vomiting

CB1 receptors in the brain stop responding
to THC in chronic cannabis users
CB2 receptors in the gut continue to
respond to THC
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•

• CHS consists of three phases:

The patient is a 20 year old male who presented to an outside hospital with a two day history of
nausea and forceful vomiting after heavy marijuana use
He was unable to hold down food, but was attempting to hydrate during this time
The patient has a history of vomiting episodes in the past, but nothing to this extent
While in the hospital, he received pantoprazole and metoclopramide, in an attempt to quell his
episodes of emesis
He was then transferred to Thomas Jefferson University Hospital (TJUH) for further management

CB2

• Recovery phase: Resolution of symptoms and a return to normal activities of daily living

TREATMENT OPTIONS
Class

Medications Prior to Arrival : No known medications prior to admission
Initial Assessment:
Height: 6’
Weight: 82.1 kg
Pertinent Labs:
138

100

CrCl: 160 mL/min

3.0

CB2 activation > CB1 activation = CHS

26

BMI: 24.53 kg/m2
15.6

15
0.8

43.3

Hospital Course

CLINICAL FEATURES
Tendency to use
extremely hot
baths/showers for relief

Nausea

Difficulty eating or
keeping food down

Weight loss

Stomach pain

Severe vomiting and/or
diarrhea, sometimes for
days or weeks

DIAGNOSTIC WORKUP
• Symptoms: recurrent abdominal pain, intractable nausea and vomiting
• CBC, BMP, lipase, LFTs, abdominal exam and X-ray

Agents

Metoclopramide, prochlorperazine, Act via dopaminergic regulation of the chemoreceptor trigger zone
promethazine, trimethobenzamide and have pro-kinetic effects on motor function of the GI tract

Serotonin
antagonists

Ondansetron, dolasetron,
granisetron

Block serotonin, an important pro-emetic neuroendocrine
transmitter, released by enterochromaffin cells within the GI tract

Benzodiazepines

Lorazepam, diazepam

Exert GABA receptor agonist-like properties with antiemetic effects
through the inhibition of medullary and vestibular nuclei associated
with nausea and emesis, and possibly of the GI tract as well

Antipsychotics

Act via high-affinity antagonism at D2 receptors in CNS-there also
Haloperidol, droperidol, olanzapine are high concentrations of D2 receptors within the chemoreceptor
trigger zone

Opioids

TRPV1 agonist

• The patient was transferred to TJUH from an outside hospital, complaining of several days of forceful
vomiting. He also reported feeling “rice crispies” in his neck
Hospital • New radiologic evidence suggestive of pneumomediastinum
Day 1
• He was made strictly NPO and he was started on IV fluids and Zofran 4mg IV every 6 hours
• He reported resolution of the “rice crispies” in his neck, despite reporting persistent nausea,
refractory to his current anti-emetics which included Zofran 4mg IV every 6 hours, Phenergan 6.25mg
IV every 6 hours, and Tigan 200mg IM every 6 hours. He remained NPO
Hospital • Thoracic surgery was consulted to investigate potential surgical options
Day 2 • Topical capsaicin 0.025% cream was applied four times daily, as it has been reported as a palliative
measure for CHS
• He continued on Zofran 4mg IV every 6 hours, Tigan 200mg IM every 6 hours, Phenergan 6.25mg IV
every 6 hours, and Ativan 1mg IV once; additionally, scopolamine 1.5mg patches were applied every
72 hours
Hospital • He reported he felt that his symptoms were improving, and his diet was advanced to a liquid diet,
Day 3
followed by a solid food trial; however, during this trial, he experienced another episode of vomiting
and was subsequently deemed not ready for discharge
• He continued Zofran 4mg IV every 6 hours and Ativan 1mg IV every 6 hours as needed
• He was made aware that his clinical scenario was related to his heavy marijuana use and was educated
to discontinue future use
Hospital
Day 4 • He suddenly reported no more episodes of nausea and vomiting, and did not require any pain
medications overnight
• He reported that his nausea dissipated around 3pm yesterday and he felt that the IV Zofran and IV
Dilaudid really improved his symptoms
Hospital
Day 5 • He was started on a regular diet, anticipating discharge if able to tolerate
• He was discharged on this day after a successful trial of an oral diet

Proposed mechanism of action in CHS

Dopamine
antagonists

235

14.6

Diagnostic Findings:
Chest CT: Diffuse subcutaneous emphysema and pneumomediastinum with extension of
air along the esophagus into the abdomen.

Agonism: worsen nausea/vomiting

• Prodromal phase: May last for years, unbeknownst to the patient; patients express nausea and
abdominal pain, particularly in the morning, but continue normal eating patterns and marijuana use.
Some even increase their use of marijuana, anticipating benefit from its anti-emetic properties
• Hyperemesis phase: Typically resolves within 48 hours. Patients experience violent bouts of
unexpected and intractable emesis. Fluids and anti-emetics are typically administered, and patients
report taking hot showers during this time. Relapse is possible if patients revert to using marijuana

Past Medical History:
• CHS (complicated by Boerhaave’s syndrome)
• CVS
Social History:
• + Marijuana smoker
• Former 1 pack/day cigarette and vape smoker (pack years unknown)
• + EtOH drinker (socially)
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PHASES OF CHS

Hot shower/bath

Hydromorphone, morphine

Bind to and activate opioid receptors within the chemoreceptor
trigger zone, producing enhanced sensitivity of the vestibular system
and delayed gastric emptying

Topical capsaicin

Capsaicin binds TRPV1 receptors triggering an influx of calcium and
sodium and the release of inflammatory neuropeptides leading to
burning and itching. The theorized mechanism of action mimics heat
activation of the TRPV1 receptor
Cannabinoid dose-dependent hypothermic effects occur due to
cannabinoids binding to CB1 receptors of the hypothalamus, which
is the thermoregulatory center of the brain. Hot showers/baths
decrease sympathetic nervous system activation resulting in
decreased heart rate and blood pressure. Another theory is
“cutaneous steal” in which cutaneous vasodilation from external
heating alters core temperature and diverts splanchnic circulation,
lessening abdominal discomfort

DISCUSSION
• Legalization of recreational marijuana has been ongoing throughout the United States, thereby
creating expanded access for patients, as well as the potential for the increased risk of hospital
admissions due to CHS
• CHS is often underdiagnosed, which may be attributed to its delay in onset. Clinicians are also
becoming more familiar with its presence
• Additionally, many patients with CHS are often misdiagnosed, due to the broad range of disorders
with similar symptomatic presentations
• Although a clearly defined mechanism behind CHS has yet to be discovered, it is prudent for
pharmacists to become familiar with the multiple modalities utilized to combat this disorder, and to
be cognizant that non-traditional therapies are vital aspects of treatment
• More research is warranted in this therapeutic area, as no clear treatment regimen has been defined
• Unfortunately, other than cessation of marijuana use, a proven cure has yet to be established
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• Toxicology screen
• Question patient directly about marijuana use and if symptoms improve specifically with hot showers
• If the patient endorses any of these symptoms, expresses marijuana use, and has positive toxicology tests, clinicians
should strongly consider a diagnosis of CHS

1.

DISCLOSURE
Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that
may have a direct or indirect interest in the subject matter of this presentation.

2.
3.
4.

Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of
capsaicin and hot water hydrotherapy in treatment. Clinical Toxicology. 2018;56(1):15-24.
Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241–249.
Richards JR. Cannabinoid hyperemesis syndrome: pathophysiology and treatment in the emergency department. J
Emerg Med. 2018;54(3):354-363.
Lapoint J, Meyer S, Yu CK, et al. Cannabinoid Hyperemesis Syndrome: Public Health implications and a Novel Model
Treatment Guideline. West J Emerg Med. 2017;19(2):380-386.

